Company: ARVN
Filing Date: 2025-10-24
Form Type: 8-K
Source: 0001628280-25-046259
Chunk: 2

Company: ARVINAS, INC.
Filing Date: 2025-10-24
Form: 8-K
Item: Item 8.01
Chunk 2
---
 currently evaluating ARV-806 in a Phase 1 clinical trial in patients with KRAS G12D - mutated advanced solid tumors.

In addition, the poster shown at the 2025 Triple Meeting showed that orally bioavailable pan-KRAS degraders have been identified that potently degrade multiple variants of KRAS and spare other RAS isoforms. A tool pan-KRAS PROTAC demonstrated robust single-agent activity and superior combination efficacy with immune checkpoint blockade compared with a pan-RAS ON inhibitor (7 complete responses compared with 2 complete responses).

Item 9.01 Financial Statements and Exhibits.